Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

forbes.com - Robert Glatter - Big Pharma And Psychedelic Medicine: Eli Lilly's $3.8 Billion Bet
Big Pharma And Psychedelic Medicine: Eli Lilly's $3.8 Billion Bet
Forbes

Human brain developing into extraordinary due to use of natural medicine On July 16, 2026, Eli Lilly announced it would acquire AtaiBeckley for up to $3.8 billion — $2.8 billion up front, with another $1 billion in milestone-linked…

globenewswire.com - Zealand Pharma - Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)
Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)
GlobeNewswire

Company announcement No. 33 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 29, 2026) Copenhagen, Denmark, July 20, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL)…

globenewswire.com - Zealand Pharma - Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
GlobeNewswire

Company announcement – No. 34 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, July 20, 2026 –…

swissinfo.ch - swissinfo.ch - Korean firm bids CHF1.5bn for Swiss pharma supplier Polypeptide
Korean firm bids CHF1.5bn for Swiss pharma supplier Polypeptide
www.swissinfo.ch

The company is offering CHF44.31 per share in cash, valuing Polypeptide at around CHF1.5 billion. Polypeptide's board of directors supports the offer, both companies announced on Monday. The major shareholder, Draupnir Holding, which holds just…

fool.com - Brendan Coffey - For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
The Motley Fool

The iShares Global Healthcare ETF (IXJ 0.56%) provides broad global sector exposure, while VanEck Pharmaceutical ETF (PPH 0.72%) offers a more concentrated, higher-yielding approach specifically focused on pharmaceutical companies. These funds both…

fool.com - Brendan Coffey - Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?
The Motley Fool

Invesco Pharmaceuticals ETF (PJP 0.30%) offers concentrated U.S. pharma exposure, while iShares Global Healthcare ETF (IXJ 0.56%) provides a more diversified, lower-cost global approach with higher assets under management and dividend yields.

thehindu.com - The Hindu Bureau - Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day
Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day
The Hindu

Hyderabad-based Indian multinational pharmaceutical and biotechnology company Natco Pharma's shares were in the spotlight on Monday after it received tentative approval from the U.S. Food and Drug Administration (FDA) for Olaparib, 100 mg, and 150…

bloomberg.com - Madison Muller - Bristol Partners With Nvidia on AI Factory for Drug Development
Bristol Partners With Nvidia on AI Factory for Drug Development
Bloomberg

Bristol Myers Squibb Co. is expanding its partnership with Nvidia Corp. to boost the computing power of an AI factory that the drugmaker say it's using to create new medicines more quickly. The tie-up is one of several between the chipmaker and…

thehindubusinessline.com - Private banks drag indices lower; PSU banks, pharma cushion losses
Private banks drag indices lower; PSU banks, pharma cushion losses
BusinessLine

Markets closed lower on Monday as disappointing net interest margins from a key private-sector lender and renewed geopolitical tensions in the Middle East kept investors cautious throughout the session, even as public-sector banks and pharma stocks…

marketbeat.com - NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 5.6% - Time to Sell?
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 5.6% - Time to Sell?
MarketBeat

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report)'s share price was down 5.6% on Monday. The stock traded as low as $30.06 and last traded at $29.9130. Approximately 698,804 shares changed hands during mid-day trading, a decline of…

marketbeat.com - OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of 'Hold' from Brokerages
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of 'Hold' from Brokerages
MarketBeat

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have been assigned an average recommendation of 'Hold' from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst…

seekingalpha.com - Driehaus Capital Management - Driehaus Micro Cap Growth Strategy Q2 2026 Commentary
Driehaus Micro Cap Growth Strategy Q2 2026 Commentary
Seeking Alpha

Driehaus Micro Cap Growth strategy outperformed the Russell Micro Growth Index, for the second quarter of 2026, appreciating 31.27% versus a gain of 28.98% for the benchmark. The June quarter was exceptional with all the major indices reporting…

republicworld.com - Hrishita Kumar - Sensex, Nifty End In Red As Bank Nifty Slumps 0.98% On Mixed Q1 Earnings; Asian Markets Trade Mixed Amid Middle East Tensions
Sensex, Nifty End In Red As Bank Nifty Slumps 0.98% On Mixed Q1 Earnings; Asian Markets Trade Mixed Amid Middle East Tensions
Republic World

Indian equity benchmarks closed lower on Monday, weighed down by weak performances across IT, banking, and auto stocks, even as select defensive sectors managed to buck the trend. The Nifty 50 settled at 24,238.50, down 95.80 points, or 0.39%…

fool.com - Andy Gould - PJP vs. IYH: Which Healthcare ETF Is the Better Buy?
PJP vs. IYH: Which Healthcare ETF Is the Better Buy?
The Motley Fool

The iShares U.S. Healthcare ETF (IYH 0.47%) provides broad exposure to the medical sector at a lower cost, while the Invesco Pharmaceuticals ETF (PJP +0.28%) offers a more concentrated bet on drug development. While both funds target American…

rediff.com - Rediff News - 10 Companies Enter Rs 1 Trillion Club, 6 Exit
10 Companies Enter Rs 1 Trillion Club, 6 Exit
Rediff.com

The number of companies with a market capitalisation of Rs 1 trillion or more rose to 114 in 2026, from 110 in the previous year. Ten companies entered the Rs 1 trillion club, while six exited it during the year. Companies that entered the club in…

Receive a Daily briefing on Pharma Industry News

Get Started